Post-doctoral position at CRCM (Campus of Luminy, Marseille France) in the field of bioinformatics applied to Pancreatic Cancer personalized therapy.

Type de poste
Dates
Durée du poste
Contrat renouvelable
Contrat non renouvelable
Date de prise de fonction
Date de fin de validité de l'annonce
Localisation
Adresse

<p>163 Av de Luminy, Campus Universitaire de Luminy</p><p>Case 915</p><p>13288</p><p>Marseille</p>
Marseille
France

Contacts
Dusetti Nelson
Email du/des contacts
nelson.dusetti@inserm.fr
Description

<p>Post-doctoral position at CRCM (Campus of Luminy, Marseille France) in the field of bioinformatics applied to Pancreatic Cancer personalized therapy.</p><p>A postdoctoral fellowship for 4 years is available from January 2019 at the Cancer Research Center of Marseille in the team of Nelson DUSETTI (translational medicine group, Pancreatic Cancer, INSERM U.1068) as part of the program &quot;Personalized Medicine in Pancreatic Cancer&quot; funded by The French National Cancer Institute (Inca).</p><p>This multidisciplinary project aims to propose new therapeutic strategies to personalize the management of Pancreatic Cancers. The goal is the identification of molecular signatures to predict the sensitivity of tumors to chemo-therapeutic drugs. We have established a collection of more than 150 pancreatic tumors for which we have determined sensitivity to different chemo-therapeutic drugs. We performed also extensive Multi-Omic analyzes on these tumors (exome sequencing of normal and tumor tissue; CNV; methylome; ChIP-seq; mRNA RNA-seq transcriptome and miRNA; we also analyzed the secretome of the cells in cultures of the same tumors).</p><p>The post doc will have to identify molecular signatures able to stratify the groups of tumors (sensitive and resistant for each drug) particularly from transcriptomic data (RNAseq). These signatures will then be validated on independent cohorts of patients. The project will be accompanied by expert teams in the field of bioinformatics. The post doc will also participate to the development of novel strategies involving single cell RNAseq methodologies (SPLiT-seq) to gain insight into implication of intra-tumoral heterogeneity in treatment resistance.</p><p>Candidates should have experience in the analysis of RNA-seq data, including of raw sequencing process, as well as good general knowledge in statistics and machine learning (supervised and unsupervised). Mastery of R in the Linux environment is required as well as a solid mastery of handling large corpora of data. Experience in single cell analyzes would be appreciated.</p><p>A CV with list of publications accompanied by a letter of motivation and 2 recommendation letters should be addressed to Nelson DUSETTI nelson.dusetti@inserm.fr.</p><p>References:</p><p>&bull; Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Lomberk G, et al. Nat Commun. 2018 May 17;9(1):1978. doi: 10.1038/s41467-018-04383-6.</p><p>&bull; Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Nicolle R et al. Cell Rep. 2017 Nov 28;21(9):2458-2470. doi: 10.1016/j.celrep.2017.11.003.</p><p>&bull; Cancer Research Center of Marseille: http://crcm.marseille.inserm.fr/en/researchteams/juan-iovanna/#c932</p>…;
Laboratoire: INSERM U.1068 Centre de Cancérologie de Marseille